The group's principle activity is to engage in the research, development and commercialisation of diagnostic technologies for the medical point-of-care and onsite environmental testing markets.The company provides a diagnostic with an immunoassay platform called RAMP® tests commercially for three cardiac markers used in the early detection of heart attack, environmental detection of West Nile virus and biodefense applications including the detection of anthrax, ricin, small pox and botulinum toxin. RAMP is used by healthcare professionals and in physicians' offices, medical clinics, hospital emergency departments and laboratories worldwide. The company has received regulatory clearance from Health Canada and the US Food and Drug Administration to market its RAMP Cardiac Marker Tests for detecting myoglobin, troponin I and CK-MB to assist in the rapid diagnosis of heart attack or acute myocardial infarction. The company has achieved CE Mark and its Quality Management Sy The group operates from United States.
